Login to Your Account

Other News To Note

Monday, January 28, 2013
• Kineta Inc., of Seattle, said it secured exclusive, worldwide development rights from the University of Utah Research Foundation to a portfolio of drug candidates based on the Conotoxin Rg1a for the non-narcotic treatment of chronic pain.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription